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Abstract
Background: Recent efforts have been made to link complex human traits and disease susceptibility to DNA copy 
numbers. The leptin receptor (LEPR) has been implicated in obesity and diabetes. Mutations and genetic variations of 
LEPR gene have been discovered in rodents and humans. However, the association of DNA copy number variations at 
the LEPR gene locus with human complex diseases has not been reported. In an attempt to study DNA copy number 
variations associated with metabolic traits and type 2 diabetes mellitus (T2DM), we targeted the LEPR gene locus in 
DNA copy number analyses.
Results: We identified DNA copy number variations at the LEPR gene locus among a Korean population using 
genome-wide SNP chip data, and then quantified copy numbers of the E2 DNA sequence in the first two exons 
overlapped between LEPR and LEPROT genes by the quantitative multiplex PCR of short fluorescent fragment (QMPSF) 
method. Among the non-diabetic subjects (n = 1,067), lower E2 DNA copy numbers were associated with higher 
fasting glucose levels in men (p = 1.24 × 10-7) and women (p = 9.45 × 10-5), as well as higher total cholesterol levels in 
men (p = 9.96 × 10-7). In addition, the significant association between lower E2 DNA copy numbers and lower level of 
postprandial 2hr insulin was evident only in non-diabetic women, whereas some obesity-related phenotypes and total 
cholesterol level exhibited significant associations only in non-diabetic men. Logistic regression analysis indicated that 
lower E2 DNA copy numbers were associated with T2DM (odds ratio, 1.92; 95% CI, 1.26~2.96; p < 0.003) in our nested 
case-control study. Interestingly, the E2 DNA copy number exhibited a negative correlation with LEPR gene expression, 
but a positive correlation with LEPROT gene expression.
Conclusions: This work suggests that a structural variation at the LEPR gene locus is functionally associated with 
complex metabolic traits and the risk of T2DM.
Background
Leptin and the leptin receptor (LEPR) are involved in
satiety and energy expenditure via central and peripheral
mechanisms. The primary site of leptin action is the
hypothalamus where the leptin receptor interacts with
the adipocyte-derived leptin signal to regulate appetite,
energy balance, and metabolism. LEPRs also regulate
energy homeostasis in peripheral tissues including skele-
tal muscle, liver, pancreas, and adipose tissue. Leptin pre-
vents obesity via LEPRs by stimulating glucose uptake
and fatty acid oxidation in skeletal muscle and liver [1-3],
and inhibits insulin secretion of pancreatic β-cells [4].
Mutations and genetic variations of the LEPR gene have
been discovered in rodents and humans. Sequencing-
based detection of LEPR  mutations demonstrated that
frame-shift or missense mutations of the LEPR  gene
caused obesity, pituitary dysfunction, hyperphagia, or
hypogonadism in humans [5,6]. In rodents, leptin recep-
tor gene mutations resulted in obesity, hyperglycemia,
hyperinsulinemia, and reduced fertility [7,8]. Common
genetic variants (e.g., SNPs) at the LEPR gene locus have
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been associated with obesity, hyperinsulinemia, type 2
diabetes mellitus (T2DM), and variations in leptin levels
in different populations. For example, three non-synony-
mous SNPs (Arg109Lys, Arg223Gln, and Lys656Asn)
have been evaluated for association studies [9-13]. There-
fore, most association studies of LEPR polymorphisms
have been performed on SNPs or deletion/insertion poly-
morphisms (DIPs). However, the association of DNA
copy number variations (CNVs) at the LEPR gene locus
with human diseases has not yet been reported.
In recent years, comprehensive human CNV maps were
assembled using various experimental platforms [14-16].
While the growing number of genome-wide association
d a t a  s e t s  c a n  b e  u t i l i z e d  t o  d e t e c t  c l i n i c a l l y - r e l e v a n t
CNVs, absolute copy number information cannot be eas-
ily determined by current quantitative assays, with the
exception of Fiber-FISH. Nonetheless, recent studies have
shown that CNVs are implicated in human diseases
including glomerulonephritis (FCGR3B) [17], HIV-1/
AIDS (CCL3L1) [18], bipolar disorder and schizophrenia
(GLUR7, CACNG2 and AKAP5) [19], neoplasia (14q12)
[20], psoriasis (DEFB) [21], and myocardial infarction
(C4B) [22].
Results
On employing a candidate gene approach to the associa-
tion study of CNVs with diabetes and metabolic traits, we
targeted the genomic locus of the LEPR gene encompass-
ing approximately 200 kb of chromosome 1. DNA copy
number analysis of the Affymetrix 50 K SNP array data
showed that the Korean population exhibited CNVs at
the LEPR gene locus (Additional file 1). Our QMPSF
experiments generated continuous variables of DNA
copy number at the LEPR locus for individuals (Addi-
tional file 2). Next, the experimental copy number infor-
mation was transformed to dichotomized DNA copy
numbers (low or high) for CNV association studies. An
appropriate copy number value (low or high) was then
assigned to each individual using either male or female
median copy number value among non-diabetic subjects
(n = 1,067) as the cutoff. The same cutoff value was used
to dichotomize copy numbers among diabetes subjects in
the nested case-control study. DNA copy numbers were
determined using only a short PCR fragment (herein
referred to the "E2 DNA", located near exon 2 of the LEPR
gene, see Figure 1) of the entire LEPR gene sequence. To
address the question as to whether this short sequence
was representative of the whole LEPR gene, we investi-
gated the CNV boundaries using PCR-based (QMPSF)
and array-based (Affymetrix SNP array 5.0) analyses. Rel-
ative DNA copy numbers were obtained by QMPSF using
primers targeting several regions along the LEPR gene
sequence. QMPSF results showed that the copy number
of the E2 DNA sequence was correlated to that of the
promoter-containing exon region at the LEPR locus, but
not to the other downstream exonic regions (Figure 1).
On the other hand, CNV analysis of the Affymetrix SNP
array 5.0 data revealed that the whole LEPR gene locus
region was highly CNV-affected, with a varied length of
CNV boundaries over the LEPR gene sequence (Addi-
tional file 1). This result indicated that the E2 DNA copy
number did not represent DNA copy numbers of the
whole LEPR gene, but a partial DNA sequence containing
the LEPROT (leptin receptor overlapping transcript)
gene at the LEPR locus.
Next, we tested the statistical significance of the associ-
ation of the E2 DNA copy number with metabolic traits.
In male non-diabetic subjects, significant differences for
some demographic characteristics were observed
between low (1X) and high (2X) copy number individuals
(Table 1). Fasting glucose and total cholesterol levels were
higher in individuals with low copy numbers of the E2
DNA at LEPR gene locus in three different age groups of
male individuals (Figure 2). The association of low copy
numbers with higher levels of obesity-related phenotypes
and total cholesterol levels remained significant in linear
regression analysis with age-and BMI-adjustments fol-
lowed by Bonferroni correction for multiple testing
among male individuals (Table 1). Among female sub-
jects, E2 DNA copy numbers were also associated with
levels of fasting glucose and postprandial 2hr insulin. On
the other hand, beneficial phenotypes for obesity-related
traits and total cholesterol levels were associated with
higher DNA copy numbers (2X) of the LEPR gene locus
in male subjects.
The copy numbers of the E2 DNA sequence at the
LEPR gene locus were used in the nested case-control
study of T2DM, in which subjects (n = 137) were
matched for age, sex, and BMI at a ratio of approximately
1:2 to control subjects (n = 258). Our case groups showed
typical demographic characteristics to diabetes subjects
(Additional file 3). For example, diabetic case subjects
had higher triglyceride, higher total cholesterol, and
lower HDL-cholesterol than those levels in non-diabetic
subjects. Logistic regression analysis showed that low E2
DNA copy numbers were associated with T2DM (odds
ratio, 1.92; 95% CI, 1.26~2.96), with a significance of P <
0.003 (Table 2).
To study biological roles of the E2 DNA copy numbers,
we compared mRNA expression levels of both LEPR and
LEPROT genes with E2 DNA copy numbers in lympho-
blastoid cell lines. The E2 DNA sequence exists immedi-
ately downstream of the overlapped exon 2 of the LEPR
and LEPROT genes. Real-time PCR analysis showed a
significant negative correlation of the E2 DNA copy num-
ber with the LEPR transcript level (R2 = 0.439, p = 1.52 ×
10-4), but a weak positive correlation with the LEPROT
transcript level (R2 = 0.135, p < 0.05) (Figure 3). More-Jeon et al. BMC Genomics 2010, 11:426
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over, the LEPR expression level was inversely correlated
with the LEPROT expression level (R2 = 0.126, p < 0.05).
This result suggests that higher copy numbers of the E2
DNA may contribute to higher transcriptional activity of
the LEPROT gene by gene dosage effect, which may be
accordingly responsible for downregulation of LEPR
gene.
Discussion
Our candidate gene approach to CNV association studies
i d e n t i f i e d  t h e  E 2  D N A  c o p y  n u m b e r  v a r i a t i o n  a t  t h e
LEPR gene locus, which was associated with metabolic
traits and the risk of T2DM. Lower copy numbers of the
E2 DNA were associated with higher fasting glucose in
both male and female non-diabetic subjects. However,
obesity-related traits and total cholesterol levels exhibited
significant association with the E2 DNA copy numbers
only in male non-T2DM subjects whereas postprandial
2hr insulin level was significantly higher only in female
non-T2DM subjects. These results suggest that the E2
DNA copy number variations at the LEPR gene locus may
contribute to glucose homeostasis and energy metabo-
lism in a different manner between male and female sub-
jects.
In our CNV association study, we observed that the
beneficial high E2 DNA copy number was associated with
lower fasting glucose levels (hypoglycemia) in both gen-
ders which are beneficial in terms of diabetes. Similar
results were reported for mouse models with LEPR sig-
naling defects [23,24]. For example, hypothalamus and
pancreas-specific LEPR signaling disruption led to fasting
hypoglycemia, hyperinsulinemia, and hypertriglyceri-
d e m i a,  h i g h l i g h t i n g  t h e  i m po r t a n t  r o l e  o f  be t a  c e l l s  i n
LEPR mediated glucose homeostasis [24]. Hypothalamic
LEPR KOVMH mice fed a low fat diet also exhibited hyper-
triglyceridemia without concomitant hypercholester-
olemia [25]. Neuronal LEPR deletion induces diabetic
phenotypes such as body weight increase, adiposity, and
hyperglycemia in proportion to hypothalamic LEPR defi-
ciency [25]. In addition, antisense-RNA mediated adipo-
cyte-specific reduction of LEPR leads to decrease in
LEPR signaling, resulting in increased adipocyte, hyper-
Figure 1 Schematic diagram of CNVs at the LEPR gene locus. Genomic structures of LEPR and LEPROT genes, including exons, are shown. E2 DNA 
content relative to the Factor VIII gene from 20 subjects is displayed in the lower panel. Primer target sites (P1 to P7) for QMPSF are indicated along 
the LEPR sequence. P2* indicates the primer target site for detection of the initial copy number at the LEPR locus. P1 and P2 primer target sites were 
highly variable for copy number among the 19 individuals tested, but the other primer sites were not.
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Table 1: Association of LEPR CNVs with metabolic traits in nondiabetic subjects.
Variables Men (n = 574) Women (n = 493)
Low CN (1X)
(n = 287)
High CN (2X)
(n = 287)
P value* P value**
(adjusted)
P value***
(corrected)
Low CN (1X)
(n = 246)
High CN (2X)
(n = 247)
P value* P value**
(adjusted)
P value***
(corrected)
Age (year) 49.1 ± 8.4 50.7 ± 8.6 0.026 - - 52.9 ± 9.0 52.5 ± 8.6 0.505 - -
Height (cm) 167.2 ± 5.7 167.6 ± 6.1 0.479 0.074 ns 153.9 ± 5.9 153.7 ± 5.6 0.887 0.716 ns
Weight (kg) 67.1 ± 9.4 66.6 ± 9.4 0.431 0.082 ns 57.3 ± 8.6 57.6 ± 7.7 0.814 0.690 ns
Pulse (counts) 61.0 ± 6.5 61.4 ± 7.2 0.418 0.439 ns 64.2 ± 7.1 63.8 ± 6.8 0.656 0.719 ns
Systolic blood pressure (mmHg) 114.0 ± 14.7 114.6 ± 13.9 0.575 0.776 ns 115.5 ± 17.6 115.8 ± 15.7 0.800 0.608 ns
Diastolic blood pressure (mmHg) 75.1 ± 11.2 74.5 ± 10.6 0.512 0.502 ns 72.7 ± 11.1 73.4 ± 10.0 0.401 0.286 ns
Distal radius Z 0.16 ± 1.23 0.48 ± 1.35 2.85E-03 0.013 ns 0.91 ± 1.48 1.08 ± 1.53 0.305 0.295 ns
Midshaft tibia Z 0.47 ± 1.06 0.68 ± 1.18 0.025 0.071 ns -0.36 ± 1.30 -0.39 ± 1.31 0.768 0.834 ns
Waist circumference (cm) 82.2 ± 7.3 81.4 ± 7.1 0.194 0.353 ns 81.0 ± 9.3 81.7 ± 9.2 0.531 0.311 ns
Hip circumferences (cm) 93.9 ± 5.6 92.2 ± 6.2 3.67E-04 6.07E-04 1.76E-02 91.9 ± 6.3 91.7 ± 6.0 0.849 0.455 ns
Waist-to-hip ratio (WHR) 0.88 ± 0.06 0.88 ± 0.06 0.080 0.074 ns 0.88 ± 0.08 0.89 ± 0.08 0.380 0.182 ns
Body fat (%) 20.5 ± 4.9 19.4 ± 4.5 6.01E-03 1.03E-03 2.99E-02 29.6 ± 5.8 30.3 ± 4.8 0.201 0.072 ns
Visceral fat (%) 0.89 ± 0.04 0.88 ± 0.04 9.45E-03 1.02E-06 2.95E-05 0.89 ± 0.05 0.89 ± 0.05 0.898 0.814 ns
Obesity degree (%) 112.2 ± 12.7 110.2 ± 12.5 0.051 5.85E-04 1.70E-02 119.9 ± 17.2 120.8 ± 15.1 0.686 0.643 ns
Body mass index (BMI) (kg/m2) 23.9 ± 2.7 23.6 ± 2.7 0.158 - - 24.2 ± 3.3 24.4 ± 2.9 0.715 - -
Total cholesterol (mg/dL) 199.1 ± 36.7 181.7 ± 32.8 3.23E-09 3.43E-08 9.96E-07 188.0 ± 34.3 180.9 ± 31.0 2.25E-02 2.50E-02 ns
HDL-cholesterol (mg/dL) 45.6 ± 8.5 44.4 ± 9.5 0.119 0.056 ns 47.7 ± 9.9 45.1 ± 9.5 7.40E-03 5.51E-03 ns
Triglyceride (mg/dL) 146.9 ± 86.1 151.4 ± 82.5 0.521 0.323 ns 122.0 ± 68.7 137.1 ± 73.2 0.016 9.11E-03 ns
C-reactive protein (mg/dL) 0.19 ± 0.31 0.20 ± 0.21 0.601 0.593 ns 0.15 ± 0.24 0.21 ± 0.52 0.232 0.220 ns
WBC (103/μL) 6.6 ± 1.7 6.4 ± 1.7 0.333 0.499 ns 5.8 ± 1.5 5.6 ± 1.4 0.099 0.083 ns
RBC (106/μL) 4.8 ± 0.4 4.7 ± 0.4 3.03E-03 0.029 ns 4.1 ± 0.3 4.1 ± 0.3 0.350 0.322 ns
Hemoglobin (g/dL) 14.7 ± 1.0 14.6 ± 1.1 0.191 0.552 ns 12.5 ± 1.3 12.4 ± 1.1 0.677 0.686 ns
Hemocritat 44.4 ± 3.2 44.1 ± 3.4 0.158 0.456 ns 37.9 ± 3.4 37.7 ± 3.5 0.348 0.357 ns
HbA1C (%) 5.5 ± 0.3 5.5 ± 0.3 0.853 0.584 ns 5.5 ± 0.3 5.4 ± 0.3 0.409 0.495 ns
Insulin_0hr (μIU/ml) 6.5 ± 4.7 6.2 ± 2.6 0.283 0.474 ns 7.6 ± 5.1 7.8 ± 3.5 0.644 0.066 ns
Insulin_1hr (μIU/ml) 32.0 ± 27.2 34.5 ± 33.2 0.324 0.195 ns 29.5 ± 26.9 37.2 ± 34.1 6.66E-03 5.38E-03 ns
Insulin_2hr (μIU/ml) 18.9 ± 18.2 18.9 ± 19.1 0.994 0.713 ns 22.1 ± 19.8 29.1 ± 24.0 8.55E-04 7.93E-04 2.30E-02J
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Glucose_0hr (mg/dL) 84.0 ± 7.5 80.3 ± 6.5 3.34E-10 4.26E-09 1.24E-07 80.7 ± 6.7 77.9 ± 5.2 3.37E-06 3.26E-06 9.45E-05
Glucose_1hr (mg/dL) 127.4 ± 34.9 128.3 ± 36.8 0.741 0.983 ns 121.7 ± 34.9 121.1 ± 31.4 0.675 0.754 ns
Glucose_2hr (mg/dL) 94.9 ± 21.4 91.1 ± 20.6 0.030 0.037 ns 103.0 ± 18.9 101.3 ± 18.9 0.200 0.200 ns
HOMA-IR 1.41 ± 1.09 1.39 ± 0.59 0.835 0.928 ns 1.70 ± 1.15 1.8 ± 0.8 0.261 0.263 ns
*: P value: t-test
**: P value: age-, BMI-adjusted linear regression test (CN values)
***: P value: obtained by Bonferroni correction for multiple testing. ns indicates none-significance (cutoff p < 0.05).
Table 1: Association of LEPR CNVs with metabolic traits in nondiabetic subjects. (Continued)Jeon et al. BMC Genomics 2010, 11:426
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triglyceridemia, and insulin resistance [26]. As presented
in our association study, the high E2 copy number indi-
viduals shared similar phenotypes with LEPR deficient
animal models. Moreover, human LEPR signaling muta-
tions also caused obesity as well as impairments of puber-
tal development and growth hormone secretion [5].
Thus, it is conceivable that higher E2 DNA copy numbers
may result in a decrease in LEPR signaling, which func-
tions in a complex manner in different tissues.
Indeed, our expression analysis of LEPR gene in LCLs
showed that the high E2 DNA copy number was signifi-
cantly correlated with downregulation of the LEPR gene
and concomitant upregulation of the LEPROT gene.
Hypothalamic  LEPR  mRNA expression is indicative of
functional LEP-LEPR signaling [27]. The LEPR and LEP-
ROT transcripts share the first two exons, which are not
translated in the LEPR gene [28]. Among the LEPR iso-
forms, the long form (LEPRb) is primarily expressed in
specific nuclei of the hypothalamus, whereas the short
isoform (LEPRa) is expressed in most tissues. These two
isoforms of LEPR have identical extracellular domains
but differ in the length of their intracellular domains,
which contributes to their different capacity for signal
transduction [29]. On the other hand, our CNV analyses
of the Affymetrix SNP array 5.0 and QMPSF revealed a
varied length of the CNV region at the LEPR gene locus.
Also, we found that the E2 DNA copy numbers did not
represent DNA copy numbers of the whole LEPR gene
but only a partial sequence containing LEPROT gene.
Thus, this finding suggests that E2 DNA copy numbers
may negatively regulate LEPR gene expression through a
gene dosage effect of LEPROT.
However, LEPROT overexpression decreases only cell
surface expression of LEPR without modifying the total
amount of LEPR [30]. In our study, the observed weak
correlation of E2 DNA copy numbers with LEPR mRNA
levels in LCLs might be ascribed to inappropriate selec-
tion of target tissues for LEPR and LEPROT expression
studies. Thus, the correlation of high E2 DNA copy num-
ber with LEPROT gene expression may be more signifi-
cant in an appropriate LEPR target tissues such as the
hypothalamus, pancreatic β-cells, or adipocytes. Eluci-
dating tissue-specific regulation of LEPR gene expression
could explain the complex pattern of association of phe-
notypes with the E2 DNA copy number variation. It
remains to be investigated whether the E2 copy number
confers a gene dosage effect of LEPROT on LEPR signal-
ing using an appropriate target tissue, and whether this
occurs via either transcriptional regulation or intracellu-
lar transport of LEPR. Alternatively, the E2 DNA
sequence may merely play a role as a direct negative tran-
scriptional regulatory sequence for the LEPR gene
expression.
Conclusion
A prior CNV analysis of Affymetrix 50 K SNP and 5.0
array chip data indicated the potential presence of CNVs
at the LEPR gene locus as well as a varied length of the
CNV region. DNA copy number measurements at the
LEPR gene locus and subsequent association studies
r e v e a l e d  t h a t  l o w e r  c o p y  n u m b e r s  o f  t h e  E 2  D N A
s e q u e n c e  a r o u n d  L E P R O T  g e n e  w e r e  a s s o c i a t e d  w i t h
detrimental phenotypes of metabolic traits (e.g., higher
fasting glucose and total cholesterol levels) as well as the
risk of T2DM. In addition, the E2 DNA copy number
exhibited a negative correlation with LEPR gene expres-
sion but a positive correlation with LEPROT gene expres-
sion. More research ma y be warranted to determine if
LEPROT expression impacts LEPR expression.
Figure 2 Total cholesterol and fasting glucose levels for individu-
als with low or high copy numbers of the E2 DNA sequence. Non-
T2DM subjects were divided into different age groups (40 s, 50 s, and 
60s) and their metabolic phenotypes were compared. (A) Total choles-
terol levels. ***: P = 2.13 × 10-6, **: P = 4.33 × 10-3, *: P < 0.05. (B) Fasting 
glucose levels. ***: P = 1.72 × 10-6, **: P = 8.39 × 10-4, *: P < 0.03.
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Methods
Study samples
Subjects described in this study include 1,204 individuals
from the Korean Genome and Epidemiology Study
(KoGES) for CNV detection and subsequent association
studies. The KoGES is a community-based prospective
cohort study of chronic diseases (e.g., diabetes and hyper-
tension) and their relationship with potential risk factors
or lifestyles, which was started in 2001. The study design,
sampling, concept and consent have been previously
described [31,32]. Briefly, a total of 10,038 individuals
participated in baseline examinations. Approximately
86.6% (n = 8,693) and 67.8% (n = 6,085) of the baseline
study subjects participated in the first and the second 2-
year follow-up studies, respectively.
For the study of CNV association with metabolic traits,
we randomly selected 1,067 non-diabetic subjects who
did not develop T2DM during either baseline or two
rounds of 2-year follow-up period from the KoGES.
WHO criteria were used to define T2DM using an oral
glucose tolerance test. Diabetes cases were defined as
subjects who were determined to have T2DM at baseline,
and then diabetes was diagnosed at least one time during
two rounds of 2-year follow-ups. For the nested case-con-
trol study, T2DM cases (n = 137) were matched for sex,
age±1, and BMI±0.1, with control subjects (n = 258) who
did not have diabetes in either baseline or during the 2-
year follow-ups. This study was approved by the institu-
tional review boards of Korea Centers for Disease Con-
trol and Prevention.
DNA copy number measurement
DNA samples used for DNA copy number measurement
were provided by the National Biobank of Korea in Korea
Centers for Disease Control and Prevention. We
extracted CNV information for candidate genes (diabe-
tes-and obesity-related) from the Affymetrix 50 K SNP
chip data in order to estimate whether CNVs were detect-
able within or near these genes in the Korean population.
The Affymetrix 50 K SNP chip data was obtained from
the Korean HapMap samples [33]. CNV analysis using
CNAT3 (Affymetrix) indicated that the LEPR gene locus
contained potential CNV regions (CNVRs) in this
Korean population (Additional file 1) [34]. In addition, we
selected a copy number invariant region (CN2-2) in chro-
mosome 2 (2q36.1) that exhibited the least copy number
variation of the CN2-2 locus among the 90 individuals
tested (Additional file 4, 5).
A potential CNV-affected region near rs2025804,
upstream of the long isoform of LEPR (LEPRb,
NM_002303), was chosen for experimental detection of
DNA copy numbers using the QMPSF method [35]. The
QMPSF reaction included the Factor VIII gene and CN2-
2 as references [34,36,37]. The relative copy numbers of a
target locus were calculated in relation to the copy num-
bers of the Factor VIII gene or CN2-2. These two normal-
izing genes yielded almost same results when used for
calculating relative copy numbers. All samples were sub-
jected to three rounds of QMPSF reactions. All reactions
were performed in duplicate.
For the justification of further CNV calling, DNA copy
numbers of Factor VIII gene were compared between
male and female subjects (Additional file 4). Based on the
r e l a t i v e  c o p y  n u m b e r s  o f  F a c t o r  V I I I  g e n e  t o  C N 2 - 2
Table 2: The nested case-control study of T2DM
Case-control E2 DNA copy number groups Odds ratio (OR) CI (95%) P value*
Low CN (1X) High CN (2X) Sum
T2DM case subjects (n = 135) 86 (63.7%) 49 (36.3%) 135 (100%) 1.92 1.26~2.96 0.003
non-T2DM control subjects (n = 258) 123 (47.7%) 135 (52.3%) 258 (100%)
Total (n = 393) 209 (53.2%) 184 (46.8%) 393 (100%)
P value*: Logistic regression analysis
Figure 3 Correlation of the E2 DNA copy number with LEPR and 
LEPROT transcription levels. Expression levels of LEPR and LEPROT rel-
ative to GAPDH were compared to the relative E2 DNA content in 32 
strains of LCLs. Relative E2 DNA content was calculated from QMPSF 
data in relation to DNA content at the Factor VIII gene locus in LCLs.

$ $ !
 
 
    !    !    !


3
$
+
*
/
*
+
$
-
1
$
!


"
#
$
>

*+,-./*$	$"$$013-*3-$-1$@,0-1$%&&&$B1+>
8$C$ !9

$$ (
8$C !$$
9
 
 

*
+
,
-
.
/
*
$
*
A


*
6
6
.
1
3

B
1
+
>Jeon et al. BMC Genomics 2010, 11:426
http://www.biomedcentral.com/1471-2164/11/426
Page 8 of 10
region, individuals of lower or higher copy number
groups were assigned to be 1X or 2X of DNA copy num-
ber for Factor VIII gene. The copy numbers (1X or 2X) of
Factor VIII gene was perfectly matched to individuals'
sex.
Fluorescent primers were designed to target a specific
region of the LEPR gene locus, encompassing over 216 kb
of chromosome 1p31, as well as the Factor VIII gene and
CN2-2 loci used for normalization of the QMPSF reac-
tions. Following optimization of the PCR reaction, multi-
plex PCR was performed with the appropriate primers
(Additional file 6). The amplicon size for the LEPR locus
was 242bp or 245bp depending on the presence of a tri-
nucleotide deletion (-/AGG, rs60086513, at chromosomal
position 65603354-65603358) and 199bp for the Factor
VIII gene. The DNA copy number of the LEPR locus in
relative to the Factor VIII reference was calculated
according to the peak height measurements of target and
reference loci. The histogram of the LEPR copy numbers
indicates two subpopulations among the non-diabetes
subjects who had either low or high copy numbers at the
LEPR locus (Additional file 2). Thus, median values of the
DNA copy number relative to Factor VIII in non-diabetic
male and female groups were used as cutoff values to call
DNA copy number values in male and female groups,
respectively. Finally, either a 'low (1X)' or 'high (2X)' DNA
copy number value at the LEPR locus was assigned to all
individuals.
Quantitative real-time PCR
Total RNA was isolated from EBV-transformed lympho-
blastoid cell lines (LCLs) that were generated from
p e r i p h e r a l  b l o o d  m o n o n u c l e a r  c e l l s  o f  p a r t i c i p a n t s .
cDNA was synthesized as previously described [38] and
then used in SYBR green PCR with the appropriate prim-
ers (Additional file 6). The difference in threshold cycles
(Ct) between GAPDH and the test genes was determined
from three experiments, each performed in triplicate.
The expression levels of the target genes were determined
relative to the expression level of GAPDH.
Statistical analyses
All data are presented as mean±SD. Student's t test was
used to compare means of the baseline measurements
between two groups. For statistical analysis, DNA copy
numbers were dichotomized as '1' for low copy number
and '2' for high copy number at the LEPR locus. Multiple
regressions were performed for association analyses of
metabolic phenotypes in non-diabetic subjects while
adjusting for age and sex, which was then corrected by
the Bonferroni method for multiple testing. Logistic
regression analysis was used for calculating P-values,
controlling for age, sex, and BMI as covariates. All analy-
ses were performed with the SPSS 12.0 Statistical Soft-
ware package.
Additional material
Additional file 1 Copy number variations at the LEPR locus in a 
Korean population. LEPR CNVs were analyzed using the Affymetrix 50 K 
SNP (A, B) and 5.0 SNP arrays (C) for 90 Korean individuals. (A) Affymetrix 50 
K SNP array data was obtained from 90 individuals from the Korean Hap-
Map project and then used to extract copy number information using the 
CNAT3 in reference to the Korean reference genome assembly of 90 indi-
viduals. For each SNP probe, standard deviation (STD) of the copy number 
(CN) values from 90 individuals was calculated and plotted along with the 
physical positions of SNP probes near the LEPR locus on chromosome 1. 
The STD of 0.25 was chosen as a cutoff value for CNV calling. A dashed box 
indicates copy number variations of the LEPR gene. (B) The Affymetrix 50 K 
SNP array data were analyzed to define CNV regions in reference to the 
Affymetrix reference genome assembly (provided by Affymetrix Inc.). The P 
value of < 0.01 was chosen to call CNVs. The CNV regions at the LEPR locus 
for 90 individuals were schematically depicted near the LEPR locus. A 
dashed box indicates copy number variations at the LEPR gene. Red bars: 
copy number gains, blue bars: copy number losses. (C) The whole genomes 
of 90 individuals were analyzed for CNV detection using the Affymetrix SNP 
array 5.0, and then compared with one specific reference genome 
(NA07357). The DNA-Chip Analyzer (dChip) was used for CNV detection 
http://www.dchip.org. dChip is a Windows software package for probe-
level and high-level analysis of gene expression microarrays and SNP 
microarrays. dChip performed invariant set normalization on the 91 chip 
data (90 Koreans and one reference). Next it calculated model-based 
expression values. Copy number variations were inferred by applying 
median smoothing method. Only CNV regions covering LEPR gene were 
shown. Assuming that CN states are 2N in the reference genome, CN states 
indicate the copy numbers of corresponding genomic locus for each indi-
vidual.
Additional file 2 Histogram of the E2 DNA content among non-T2DM 
subjects. E2 DNA content was calculated relative to the DNA content at 
the Factor VIII gene locus from QMPSF data and then plotted to display the 
distribution pattern of E2 DNA copy numbers among the non-diabetes 
subjects. The median copy numbers in the men's and women's groups 
were used to divide them into two subpopulations of lower and higher E2 
DNA copy number individuals. The E2 DNA content was then dichoto-
mized into 'lower' or 'higher' copy number groups.
Additional file 3 Characteristics of case-control subjects. *: Student's t-
test for difference between low and high CN groups within either cases or 
controls. **: Student's t-test for difference between T2DM cases and non-
T2DM controls.
Additional file 4 Justification of the QMPSF-based CNV calling using 
Factor VIII and CN2-2 references. A) Experimental validation of the CN2-2 
copy number invariant region using QMPSF. CNV analysis of the Affymetrix 
50 k SNP array data for 90 individuals identified copy number invariant 
regions with the least standard deviation of copy number (CN) values in the 
CNAT3 analysis. Relative copy numbers of the CN2-2 region were calculated 
in relative to the Factor VIII gene reference from 35 individuals. Error bars 
indicate standard deviations from three independent QMPSF reactions. 
Each reaction was performed in duplicate. Relative copy numbers of CN2-2 
region to Factor VIII gene exhibited 7.3% of coefficient of variation (CV), 
suggesting that CN2-2 can be used as a good internal control of further 
QMPSF reactions. B) Copy number distribution of Factor VIII gene in male 
and female subjects. Total individuals (n = 1,202) were clearly divided into 
two subgroups (male and female groups) by relative DNA copy numbers of 
Factor VIII gene to CN2-2 region. Individuals of lower or higher copy num-
ber groups were assigned to be 1X or 2X for Factor VIII gene. The DNA copy 
numbers (1X or 2X) of Factor VIII gene were perfectly matched to individu-
als' sex.
Additional file 5 Copy number invariant regions. a: Copy number val-
ues (CN) of each SNP probe were obtained from CNV analysis of 90 individ-
uals using the CNAT3. b: Average of copy number values of 90 individuals 
for each SNP probe. c: Standard deviation of copy number values of 90 indi-
viduals for each SNP probe. d: Average copy number values of all SNP 
probes for 90 individuals within the CNV region. e: Standard deviations of all 
probes for 90 individuals within the CNV region.
Additional file 6 Primers used in QMPSF and real-time PCR.Jeon et al. BMC Genomics 2010, 11:426
http://www.biomedcentral.com/1471-2164/11/426
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CNV: copy number variation; QMPSF: quantitative multiplex PCR of short fluo-
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